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Abstract
Translational  research  requires  large  patient 
populations. A single research institute is not able to 
build up such a population in a short period of time. 
The String of Pearls Initiative (in Dutch “Parelsnoer 
Initiatief”, PSI) is a joint effort by the eight academic 
medical  centers  in  the  Netherlands  to  built  an 
infrastructure  for  joint  biobanking  as  to  meet  this 
challenge  of  establishing  large  collections  of  data 
and samples in relevant medical domains.
Introduction
With  the  emergence  of  the  notions  of  translational 
research  and  personalized  health  care  there  is  an 
increasing  need for large study populations. Recent 
studies on genomewide association studies used large 
amounts of cases which cannot be collected in one 
single centre. For example,the study to identify risk 
alleles  for  multiple  sclerosis  included  nearly  8000 
cases
1.  The collaboration among the eight academic 
medical centers  (UMCs) in the Netherlands to build 
a biobank for Inflammatory Bowel Disease (IBD) has 
served  as  a  model  for  an  initiative  to  develop  a 
national infrastructure to support sharing of data and 
samples in specific medical domains. This contribu-
tion describes the objectives of this initiative, known 
as PSI (shorthand for ParelSnoer Initiatief = String of 
Pearls  Initiative
§).  We  will  outline  the  general 
principles that will govern the development of various 
biobanks that are part of this four years project. 
Objectives of PSI
The main objective of PSI is to build an infrastructure 
that will facilitate the collection of clinical data and 
biological samples for multi-center studies among the 
eight  UMCs  in  the  Netherlands.  This  infrastructure 
allows for sharing data that are collected both in the 
clinical  process  and  specifically  for  the  biobank  at 
§ In our metaphor, the infrastructure is the string that will link the 
eight UMCs to enable the creation of the  biobanks (the pearls).
hand as well as information about samples that are 
available from the included cases.
As  to  demonstrate  the  feasibility  of  the  approach, 
eight medical domains have been identified for which 
prospective biobanks will be developed. These eight 
domains  are  IBD,  diabetes,  cerebral  vascular 
accidents,  leukemia,  neuro-degenerative  diseases, 
arthritis/arthrosis,  hereditary/familial  colorectal 
cancer and kidney failure. 
By  doing  so,  we  are  building  eight  biobanks  that 
cover  a  large  part  of  the  Dutch  patient  population 
with the selected problems. This will allow us on the 
one hand to quicker address research questions that 
arise in those domains and on the other hand get more 
powerful results due to the larger collection of cases 
available for analysis.
We use a broad definition of biobank. In PSI, a bio-
bank is a collection of a) clinical information – obser-
vations, lab tests, image data etc – of patients with a
specific condition and b) a description of the samples 
obtained  from  processing  body  material  –  tissue, 
blood – from those patients and c) the samples. 
Development issues in PSI
The PSI project has 4 domains for development. 
a) The clinical domains.
Each clinical domain is defining the  content of their 
biobank.  The  clinical  representatives  of  the  UMCs 
are  also  responsible  for  the  implementation  of  the 
mechanisms  to  collect  the  agreed  upon  data  and 
material  for  the  biobank.  The  exploitation  of  the 
biobanks is not part of the PSI project.
b) Central Infrastructure
The general architecture is based on the notion that 
each  UMC  will  publish  its  consolidated  data  in  a 
shared datawarehouse (see figure 1). This dataware-
house  will  have  an  export  function  as  to  make  the 
data  available  for  research  purposes.  For  the  time 
being the central infrastructure will only deal with the 
data and sample domains. The central infrastructure 
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the  samples  stored  in  the  various  UMCs.  For  a 
specific research project, these samples first need to 
be  further  analyzed  before  genomic  data  will  be 
available  for  bioinformatics  and  statistical  analysis. 
Hence  we  will  not  provide  –  at  least  for  the  time 
being  –bioinformatics  tools  through  the  central 
infrastructure. We will explore whether data that is 
generated by genomics analysis of the samples should 
be made available in the central database for future 
use. Alternatively, a reference to another data store 
where these data are available could be included. 
Figure  1:  Global  architecture  of  the  IT 
infrastructure
c) Local infrastructure and implementation
A  main  effort  in  PSI  is  the  implementation  of  the 
workflows and IT infrastructure at the UMC level to 
facilitate  data  and  sample  collection.  As  is  evident 
from figure 1, each UMC can and will have its own 
infrastructure that has to deliver the data to the central 
infrastructure. In our concept the interface messages 
to deliver the data to the central infrastructure will be 
defined. It is up to each UMC to decide how these 
messages  will  be  implemented.  Developing  a  local 
infrastructure for systematic collection of high quality 
data  and  samples  in  the  specified  domains  goes 
beyond the implementation of a data capture tool. It 
has to do with structuring clinical processes and in 
some  circumstances  with  a  redesign  of  the  patient 
flow  as  to  accommodate  the  additional  activities 
necessary  for  obtaining  samples  and  data  to  be 
included  in  the  biobank.  It  has  been  argued  that 
secondary  use  of  data  from  an  electronic  patient 
record  has  a  great  potential  for  clinical  research
2. 
However,  clinicians  with  research  experience  have 
expressed their concern that a gap exists between the 
quality  requirements  for  data  for  clinical  care  and 
those  for  data  used  for  research  purposes.  As  to 
bridge  this  quality  gap  a  careful  implementation of 
data  acquisition  processes  for  the  PSI  biobanks  is 
necessary.  The  best  approach  also  depends  on  the 
type of cases to be included and the local working 
environment.
d) Frame of Reference
A special working group has developed a frame of 
reference  that  defines  largely  the  rules  for  the 
development  and  implementation  of  the  biobank 
infrastructure as well as for the collaboration in the 
clinical domains. It covers the business architecture 
(how to do biobanking), the information architecture 
(the choice of standards and rules for how to develop 
and  maintain  the  information  models  for  the 
biobanks) as well as the technical architecture of the 
infrastructure. The purpose of the frame of reference 
is  to  support  a  coherent  development  of  the 
infrastructure as well as of the biobanks for the eight 
clincal  domains.  It  defines  general  principles  that 
hold for each UMC and/or each clinical domain. It 
also provides the basic principles on which the central 
infrastructure is going to be developed. 
In  the  business  domain  the  following  aspects  have 
been  elaborated:  Legal  aspects,  Ethical  aspects, 
quality aspects and information security. Since it is 
foreseen  that  the  biobanks  could  be  used  by 
commercial  partners,  there  has  to  be  a  legal 
framework that defines clearly the privacy aspects of 
the  data  and  samples  provided  by  the  patients,  the 
rights the patients have with respect to the use of their 
data and samples. On the other hand the participating 
UMCs have an interest in protecting and valorization 
of their intellectual property. Within the legal domain 
clear guidelines are provided how to specify the rules 
for ownership of the biobank. It also identifies issues 
to be included in the procedures on how to release 
data and samples from a biobank to interested parties. 
Ethical aspects dealt with include the nature of the 
informed  consent  and  the  approval  by  Institutional 
Review  Boards  for  secondary  use  of  clinical  data, 
collection  of  additional  data  and  obtaining  body 
materials for biobanking purposes without yet a clear 
research question and study design.  Guidelines exist 
in  The  Netherlands  for  the  use  of  clinical  data  en 
body materials, left over from diagnostic procedures 
and surgery
3,4. These guidelines only partly apply to 
the PSI activities. In most selected clinical domains 
additional body materials (in particular blood) will be 
collected.  A  few  UMCs  do  already  have  broad 
informed consent forms to collect body materials for 
future research. Some haven’t specified the scope of 
the research, others have restricted the scope to the 
clinical condition (more or less broadly defined) of 
the patient that has provided the material. Given these 
differences it has not been possible to develop one 
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111general  informed  consent  for  PSI.  There  is  a 
reference  informed  consent  that  can  be  adapted 
locally to the particular situation in the UMC. 
It is recognized that data and samples have to be of 
the highest quality to be competitive with others that 
offer access to patient data and samples. Guidelines 
for  quality  management  within  the  eight  selected 
domains have been defined. The main focus is on the 
collection and processing of the material to be inclu-
ded in the biobanks. Approaches for quality control 
of the collected data have been proposed as well. It is 
recognized  that  the  highest  possible  quality  is 
desirable, but the UMCs should be able to implement 
these guidelines in their organization. A balance has 
to be found between what is theoretically desirable 
and practically feasible.  
It is imperative that the privacy of the donors of the 
material  in  the  biobanks  is  protected.  The  highest 
level  of  protection  would  be  the  storage  of 
anonymous data. However, such an approach would 
make  the  inclusion  of  follow-up  data  difficult.  We 
have  chosen  a  pseudonymisation  approach.  Some 
identifying data will be used to create a code number 
that is not directly translatable in identifying informa-
tion.  The  code  creation  is  standardized  among  the 
UMCs. It is expected that this year a law will pass 
that  will  require  the  use  of  our  Citizen  Service 
Number  (BSN)  in  health  care  to  support  sharing 
clinical  data  among  health  care  organizations.  This 
number will form the basis for the pseudonymisation 
process. By using the BSN, patients that move from 
one part of the Netherlands to another part still can 
contribute their clinical (follow-up) data and material 
to the biobank. As to further protect the privacy of the 
patients  the  data  export  implemented  in  the  central 
infrastructure  will  have  a  second  pseudonymisation 
which is export dependent. This guarantees that data 
in two different extracts can not be linked on the basis 
of the identifiers. The central infrastructure should be 
able to trace back from the extract pseudo code to the 
central pseudo code as to be able to link the data in 
the  extract  with the samples in the biobanks at the 
various UMCs. The UMCs are responsible for being 
able to trace back from the central pseudo code to the 
BSN and hence to the patient and its data. 
In  the  information  architecture  domain  the  main 
topic addressed is the PSI Information Model, which 
forms the basis for the specification of each of the 
eight biobanks (both for the clinical data as for the 
description of the samples, possibly including also the 
storage of results of -omics analysis on the samples in 
the  biobank).  We  have  chosen  to  base  this  PSI 
Information model on the base classes of the HL7v3 
RIM  (Act,  ActRelationship,  Entity,  Role,  Partici-
pation,  RoleLink).    Concept  models  will  be 
developed for information that will be collected in the 
different  clinical  domains.  Examples  are  Smoking 
status,  Donor/patient,  previous  diagnoses,  biobank 
sample.  In  contrast  with  the  clinical  environment, 
there is less need for process information. Hence the 
models can be simpler than those developed for the 
clinical applications. For these developments we also 
consider  other  standardization  activities  like  the 
CDISC  efforts  to  describe  their  models  in  HL7v3 
format and the work in progress on the representation 
of –omics data in the HL7v3. Standardization in this 
respect may also make local implementation a more 
tractable task. A further concern is the use of coding 
systems  for  the  systematic  recording  of  clinical 
observations  and  laboratory  results.  SNOMED  CT, 
LOINC and other relevant coding systems are being 
considered. Another issue that has to be addressed is 
the  traceability  of  the  data.  Study  sponsors  may 
require that it can be proven that no data tampering 
has taken place. This means that each data item has to 
be traceable to its source. This also means that at the 
central  infrastructure  version  management  may  be 
required.  This  issue  needs  further  study  and 
determines  also  to  a  certain  extent  the  data  quality 
that can be guaranteed upfront. 
The technical architecture domain mainly deals with 
the  central  infrastructure.  The  latter  can  be  largely 
considered as an integration architecture that should 
be  able  to  integrate  the  data  from  the  UMCs  that 
participate in a clinical domain into one coherent data 
set. Rather than directly storing the collected data in 
the central data base, it is foreseen that the UMCs will 
upload  data  to  the  central  infrastructure  at  regular 
time  intervals.  The  pseudonymisation  code  allows 
linkage  of  data  of  the  same  donor  over  time  as  to 
allow follow-up data collection schedules (e.g. during 
yearly check-ups). 
Timeline of the PSI project
The  PSI  project  formally  started  at  1-1-2007.  The 
first  11  months  of  the  project  have  been  used  to 
develop  the  frame  of  reference  and  the  detailed 
definitions of the clinical domains in terms of the type 
of patients to be included, the clinical and laboratory 
data and the body material that will be collected and 
how the material will be processed. Implementation 
of all eight clinical domains at the same time is risky 
hence  one  domain  has  been  selected  to  be 
implemented early in the project in all eight medical 
centres (IBD) while the others will follow later. Each 
UMCs will define their own development and imple-
mentation  plans  for  the  years  2008-2010.  This 
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of  the  eight  clinical  domains.  Figure  2  shows  the 
various phases of PSI.
The  development  of  the  central  infrastructure  will 
take place in 2008, including a complete test of the 
functionality for data integration. 
Each  of  the  UMCs  will  start  to  implement  IBD
domain  early  in  2008.  The  timeframe  of  the 
implementation of the other domains will depend on 
the local situation.
In  the  course  of  2010  all  biobanks  should  become 
operational in all UMCs. Furthermore, it is foreseen 
that in 2010 the data of at least one biobank will be 
used to answer specific clinical research questions.
Fase 1:
Preparation
April 2007 
– Nov 2007
Fase 2:
Development and 
implementation
Dec 2007 – Dec 2009
Fase 3:
Exploitation
Jan 2010 –
Dec 2010
Figure 2 Phases of the PSI project
The PSI from a local project manager perspective
Implementation  of  the  processes  and  procedures  to 
collect  data  and  material  for  each  of  the  eight 
domains in the local environment of an UMC is a big 
challenge. At this level the following aspects are to be 
dealt  with:  a)  data  and  material  collection  and 
processing  procedures,  b)  the  IT  infrastructure  for 
capturing  all  relevant  data  and  c)  the  physical 
realization of the (centralized) freezer capacity of the 
biobank. There is no general approach to these issues 
since  what  has  to  be  done  depends  on  the  local 
situation.  In  the  following  we  describe  the  early 
experiences  with  the  local  implementation  at  the 
Maastricht University Medical Center (MUMC+).
The clinicians from the various clinical domains do 
have a high level of ambition. PSI is not only seen as 
a means to advance clinical research, but also as a 
good reason to review how clinical research can best 
be integrated with clinical care. Due to the variety of 
diseases covered, various situations occur. There are 
large  differences  in  how  the  clinical  data  can  be 
collected.  On  the  one  hand,  one  has  the  leukemia 
patients who get their treatment in the hospital. Many 
of these patients already participate in clinical trials. 
Building up a biobank for this kind of patients should 
be rather straightforward.  Still, there are challenges 
to redesign the data collection process for the clinical 
trials in such a way that it can also be used for the PSI 
biobank. At the other end of the spectrum there is the 
biobank on kidney failure that tries to capture patients 
in the early phase of the disease before they develop 
end-stage kidney failure requiring dialysis or kidney 
transplantation.  To  address  the  problem  of  early 
detection  of  kidney  failure  a  special  clinic  will  be 
developed.  This  clinic  would  be  an  excellent  entry 
point for patients to be included in the study. Since 
such a clinic will be largely run by nurse practitioners 
who are supervised by nephrologists, proper record 
keeping is a prerequisite. Here it will be possible to 
integrate data collection for the biobank with clinical 
work processes.  There are, however, logistic issues 
tp be dealt with since the special clinic will be located 
at a distance from the biobank laboratory.  
There are other diseases where patients – after they 
have been stabilized – are handed over from speciali-
zed care to primary care. For such situations a provi-
sion has to be developed that will approach patients 
that  participate  in  a  biobank  for  a  follow-up  visit. 
Such  activities  take  place  outside  the  regular  care 
provision.  Hence  a  kind  of  outpatient  facility  for 
research has to be developed that will take care of 
these situations.
Given these different contexts in which the data and 
material has to be collected, the implementation for 
each clinical domain is approached as a project on its 
own. These projects will be coordinated through the 
local PSI project management as to identify common 
issues that may require a common solution.
The IT infrastructure at each of the UMCs is quite 
different.  This  means  that  also  at  the  local  level, 
different solutions will be developed to address the 
challenges of PSI. The academic hospital of MUMC+
is replacing their IT infrastructure, including ERP and 
EPR functionalities. This offers us the opportunity to 
develop a research IT infrastructure that is integrated 
with the clinical IT. Research oriented electronic data 
capture  forms  will  be  an  integral  part  of  the  EPR
system.  These  forms  should  be  accessible  for  both 
clinicians  and  research  nurses.  Other  aspects  of 
support  of  clinical  research  like  registration  of 
informed consent, order management of samples and 
tests for research purposes, will be integrated in the 
Hospital  Information  System  as  well.  The  IT
infrastructure  to  support  PSI  is  being  developed  in 
such a way that also local clinical research projects 
can be facilitated as well.
MUMC+ has already a centralized biobank facility. 
Material can be processed according to agreed upon
Standard Operating Procedures. and stored in freezers 
at  different  temperatures.  A  Biobank  Information 
System    (BIS)  keeps  track  of  all  samples  in  the 
biobank. It documents the processing of the samples 
at the biobank and provides information on the study, 
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location  of  the  subsamples.  Integration  of  the  BIS 
with  the  new  IT  infrastructure  is  one  of  the  local 
objectives in the PSI project. 
Discussion
PSI is based on experiences in The Netherlands with 
earlier  registrations  of  data  of  HIV/AIDS  patients. 
These  registrations  have  been  the  basis  for  several 
research projects in this domain. The availability of a 
comprehensive  set  of  data  on  these  patients  has 
attracted  funding  for  such  research  projects.  The 
business model for PSI is that the availability of bio-
banks is attractive for parties with particular research 
questions. Since the data collection has already taken 
place to a large extent. The biobank can be used as a 
pool from which the most appropriate cases can be 
retrieved.  In  addition,  the  participation of the eight 
UMCs in PSI will create a much larger biobank than 
any of the UMCs could have created on its own.
There are other initiatives to facilitate (translational) 
research. In The Netherlands, PALGA provides since 
1971 a central archive of all reports created by the 
pathologists in the 70 pathology departments in Dutch 
hospitals
5. The PALGA data base is being used both 
for clinical care and for research purposes. It allows 
researchers to find cases, based on the diagnoses in 
the pathology reports and to retrieve the samples from 
the  participating  centers  for  additional  analysis. 
PALGA  is  limited  in  the  sense  that  it  covers  only 
cases from which tissue has been obtained during the 
care process. Hence it covers not all diseases. Also 
clinical observations are not included and have to be 
retrieved later on.
Similar  to  PALGA  there  is  the  Shared  Pathology 
Informatics Network (SPIN) in the USA
6. Rather than 
having  a  centralized  data  base  of  the  pathology 
reports,  SPIN  provides  access  to  data  at  the 
participating sites. 
There are other initiatives that aim at linking various 
data  and  information  sources  for  translational 
research.  Examples  are  caGRID  (building  the 
infrastructure) and caBIG aiming at the development 
of  the  bioinformatics  tools  that  will  bring  together 
data, tools, organizations and scientists in a federated 
environment
7. The networks focus on cancer research. 
The scope of PSI is much boader as it will support 
also non-cancerous diseases.
Conclusion
PSI  is  a  challenging  project  that  will  enable  the 
UMCs  in  The  Netherlands  to  build  biobanks  that 
extend beyond what is possible in any of the UMCs 
alone  or  by  domain  specific  collaborations.  Due  to 
the  collaborative  developments  that  go  beyond  a 
single  domain,  it  is  possible  to  define  general 
principles  that  should  be  applicable  for  any  new 
clinical  domain  that  would  like  to  use  the 
infrastructure. Reuse of information models, standard 
operating  procedures  and  the  organizational  infra-
structure will make it easier to set-up future collabo-
rations. The focus on standardization of procedures, 
data  management  and  data  validation  in the UMCs 
combined  with  central  quality  assurance  will  make 
these biobanks attractive for others. 
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